Edward G. Garmey

Randomized Phase II Study of Erlotinib Plus Tivantinib Versus Erlotinib Plus Placebo in Previously Treated Non–Small-Cell Lung Cancer

Lecia V. Sequist, Joachim von Pawel, Edward G. Garmey et al. · Journal of Clinical Oncology · 2011 · 379 citations · Full text

Longitudinal Changes in Obesity and Body Mass Index Among Adult Survivors of Childhood Acute Lymphoblastic Leukemia: A Report From the Childhood Cancer Survivor Study

Edward G. Garmey, Qi Liu, Charles A. Sklar et al. · Journal of Clinical Oncology · 2008 · 257 citations · Full text

First-in-human phase 1/2a trial of CRLX101, a cyclodextrin-containing polymer-camptothecin nanopharmaceutical in patients with advanced solid tumor malignancies

Glen J. Weiss, Joseph Chao, Jeffrey D. Neidhart et al. · Investigational New Drugs · 2013 · 219 citations · Full text

Oncology, Polymer-drug Conjugate, Medicine +7

Phase I Trial of a Selective c-MET Inhibitor ARQ 197 Incorporating Proof of Mechanism Pharmacodynamic Studies

Timothy A. Yap, David Olmos, André T. Brunetto et al. · Journal of Clinical Oncology · 2011 · 193 citations · Full text

Translational Impact of Nanoparticle–Drug Conjugate CRLX101 with or without Bevacizumab in Advanced Ovarian Cancer

Elizabeth Pham, Michael J. Birrer, Scott Eliasof et al. · Clinical Cancer Research · 2014 · 93 citations